[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].

Nobuki Hayakawa, Atsushi Suzuki

研究成果: Review article

4 引用 (Scopus)

抄録

Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

元の言語English
ページ(範囲)1383-1390
ページ数8
ジャーナルClinical calcium
22
発行部数9
出版物ステータスPublished - 09-2012

Fingerprint

Osteoporotic Fractures
Hypoglycemic Agents
Osteoporosis
Diabetes Mellitus
Incretins
Medicine
Bone and Bones
Thiazolidinediones
Dipeptidyl-Peptidase IV Inhibitors
Mesenchymal Stromal Cells
Type 2 Diabetes Mellitus
Meta-Analysis
Clinical Trials
Safety
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

@article{15de73ed94db4547a0e730537ef8de9d,
title = "[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].",
abstract = "Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.",
author = "Nobuki Hayakawa and Atsushi Suzuki",
year = "2012",
month = "9",
language = "English",
volume = "22",
pages = "1383--1390",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "9",

}

[Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture]. / Hayakawa, Nobuki; Suzuki, Atsushi.

:: Clinical calcium, 巻 22, 番号 9, 09.2012, p. 1383-1390.

研究成果: Review article

TY - JOUR

T1 - [Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].

AU - Hayakawa, Nobuki

AU - Suzuki, Atsushi

PY - 2012/9

Y1 - 2012/9

N2 - Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

AB - Type 2 diabetes is closely associated with fragility fracture risk. Metabolic control of diabetes may improve bone status, but several anti-diabetic medicines could directly affect bone metabolism. Thiazolidinediones (TZD) may have a negative effect by switching mesenchymal progenitor cells to adipose rather than bone tissue. Clinical trials and meta-analyses showed that elderly women taking TZD could be at increased risk of fractures. On the contrary, in vitro studies suggest that incretin mimetics and incretin enhancers could positively regulate bone metabolism. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance serum incretin concentration, have been reported to reduce clinical fractures. However, further studies would be required for their long term-efficacy and safety on bone metabolism.

UR - http://www.scopus.com/inward/record.url?scp=84875103339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875103339&partnerID=8YFLogxK

M3 - Review article

C2 - 22932293

AN - SCOPUS:84875103339

VL - 22

SP - 1383

EP - 1390

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 9

ER -